In this study, we used the data from our hospital to explore the proportion of KRAS in all patients and found that KRAS G12C and TP53 mutations could appear at the same time, and KRAS G12D mutations and ROS1 rearrangement were likely to be present in one tumor at the same time. Here, ROS1 is linked to neoplasm.